DRUG SAFETY

Scope & Guideline

Elevating Standards in Pharmacological Research

Introduction

Immerse yourself in the scholarly insights of DRUG SAFETY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0114-5916
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1990 to 2024
AbbreviationDRUG SAFETY / Drug Saf.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

The journal 'Drug Safety' focuses on research related to the safety and efficacy of drugs and therapeutic interventions. It encompasses a broad spectrum of topics that include pharmacovigilance, adverse drug reactions, and risk management strategies. The journal aims to contribute significantly to the understanding and improvement of drug safety practices globally.
  1. Pharmacovigilance and Drug Safety Monitoring:
    This area covers the systematic collection, analysis, and interpretation of data related to adverse drug reactions (ADRs) and other drug-related problems. It aims to improve safety and efficacy in drug use through ongoing monitoring.
  2. Risk Assessment and Management:
    Research focusing on identifying, assessing, and managing risks associated with drug therapies, including the development of frameworks for safer medication use in various populations.
  3. Real-World Evidence and Data Analysis:
    Utilizing real-world data sources to analyze drug safety outcomes, effectiveness, and patterns of drug usage. This includes studies using electronic health records and spontaneous reporting systems.
  4. Methodological Innovations in Drug Safety Research:
    Development of new methodologies and technologies (e.g., machine learning, big data analytics) for signal detection and causal inference in pharmacovigilance.
  5. Patient-Centric Approaches to Drug Safety:
    Research that emphasizes the role of patients in pharmacovigilance, including patient-reported outcomes and experiences related to drug safety.
  6. Special Populations and Vulnerable Groups:
    Studies focusing on drug safety in specific populations, such as pregnant women, children, and the elderly, to address unique safety concerns and ensure tailored risk management.
The journal 'Drug Safety' has seen a shift in focus towards several emerging themes in drug safety research. These trends reflect the evolving landscape of pharmacovigilance and the need to address contemporary challenges in drug safety management.
  1. Integration of Artificial Intelligence and Machine Learning:
    There is a growing emphasis on the use of AI and machine learning technologies in pharmacovigilance for signal detection, data analysis, and improving reporting accuracy.
  2. Focus on Vaccine Safety and Monitoring:
    Following the COVID-19 pandemic, there has been a significant increase in research related to vaccine safety, particularly regarding the monitoring of adverse events associated with COVID-19 vaccinations.
  3. Patient Engagement and Involvement:
    Emerging research emphasizes the importance of involving patients in pharmacovigilance processes, including patient-reported outcomes and experiences, to enhance drug safety practices.
  4. Real-World Data Utilization:
    The use of real-world data for evaluating drug safety and efficacy is trending, with studies focusing on how these data can inform regulatory decisions and clinical practice.
  5. Polypharmacy and Drug-Drug Interaction Studies:
    Research addressing the complexities of polypharmacy and drug-drug interactions is gaining prominence, reflecting the need to understand safety in patients taking multiple medications.
  6. Ethical Considerations in Pharmacovigilance:
    Emerging discussions around the ethical implications of pharmacovigilance practices, particularly regarding data privacy and the responsibilities of stakeholders in drug safety.

Declining or Waning

While 'Drug Safety' continues to cover a wide range of topics, some areas have seen a decline in focus as emerging themes gain traction. This section highlights those waning scopes that may be receiving less attention in recent publications.
  1. Traditional Pharmacovigilance Methods:
    There is a noticeable decline in the publication of papers focusing solely on traditional pharmacovigilance methods, as newer technologies and data sources are increasingly prioritized.
  2. General Drug Safety Studies Without Specific Contexts:
    Research that lacks a specific context or fails to address contemporary issues in drug safety may be receiving less attention, as the emphasis shifts towards studies that are more relevant to current healthcare challenges.
  3. Single-Agent Drug Studies:
    Studies focusing solely on the safety of single agents without considering polypharmacy or drug-drug interactions are becoming less prominent, reflecting a broader understanding of the complexities of real-world medication use.
  4. Pharmacovigilance in Low-Resource Settings:
    While still important, the specific focus on pharmacovigilance in low-resource settings may be waning as the journal expands its scope to include more global and comprehensive approaches.

Similar Journals

Current Drug Safety

Illuminating the Path to Safer Therapeutics
Publisher: BENTHAM SCIENCE PUBLISSN: 1574-8863Frequency: 3 issues/year

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

Drugs-Real World Outcomes

Unveiling the true effects of drugs in everyday life.
Publisher: SPRINGERNATUREISSN: 2199-1154Frequency: 4 issues/year

Drugs-Real World Outcomes, published by SPRINGERNATURE, is an influential open access journal dedicated to the dissemination of research concerning the real-world impact of pharmacological therapies. Since its inception in 2014, this journal has established a significant presence in the field of Pharmacology, evidenced by its classification in the Q2 quartile for 2023 and a Scopus rank of #141 out of 272 in the medical pharmacology category, placing it in the 48th percentile. The journal’s scope encompasses a diverse range of studies aimed at bridging the gap between clinical research and practical outcomes, making it an essential resource for researchers, healthcare professionals, and students alike. Located in Switzerland, Drugs-Real World Outcomes allows researchers unfettered access to vital data, enhancing knowledge translation and improving health care practices. As it continues to evolve, the journal remains committed to fostering high-quality research that informs and advances the field of pharmacological therapies.

International Journal of Clinical Pharmacy

Connecting Scholars and Practitioners for a Healthier Tomorrow
Publisher: SPRINGERISSN: 2210-7703Frequency: 6 issues/year

The International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Fostering Insights in Pharmacology and Toxicology for Better Health
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

BMC Pharmacology & Toxicology

Fostering collaboration in pharmacology and toxicology.
Publisher: BMCISSN: Frequency: 1 issue/year

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

Iranian Journal of Pharmaceutical Research

Pioneering research at the forefront of pharmacology and toxicology.
Publisher: BRIEFLANDISSN: 1735-0328Frequency: 4 issues/year

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

European Journal of Pharmacology

Shaping the future of pharmacology through impactful scholarship.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

Therapeutic Advances in Drug Safety

Exploring New Horizons in Pharmacological Safety
Publisher: SAGE PUBLICATIONS LTDISSN: 2042-0986Frequency: 1 issue/year

Therapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.

Expert Opinion On Drug Safety

Elevating Standards in Pharmacological Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1474-0338Frequency: 6 issues/year

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

ANNALS OF PHARMACOTHERAPY

Fostering Excellence in Medical Research and Education
Publisher: SAGE PUBLICATIONS INCISSN: 1060-0280Frequency: 12 issues/year

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.